Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical, Inc. (NASDAQ: ISRG) reported second-quarter revenue growth of 4% year-over-year to $1.52 billion, +6% on a constant currency basis, missing the consensus of $1.56 billion. The gross margin contracted by 270 bps to 67.2%.

Intuitive Surgical Stock Plunges After Q2 Results Miss Street Expectation

Intuitive Surgical (ISRG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Intuitive Surgical (ISRG) This Earnings Season?

Johnson & Johnson

Stryker

Zimmer Biomet Hlds

While Johnson & Johnson's ( JNJ , Financial) Medtech sales were lower in the second quarter, revenue from hips and knee replacements was on target or above, a development that could spill over into segment competitors Stryker Corp. ( SYK , Financial) and Zimmer Bioment Holdings Inc. ( ZBH , Financial), as well as robotic surgery leader Intuitive Surgical Inc. ( ISRG , Financial), analysts said in a Fierce Pharma article.

J&J Medtech Outlook Boosts Shares of Stryker, Biomet and Intuitive

Abbott Labs

Moderna

These players are trading at bargain prices today.

3 Healthcare Stocks That Could Help Set You Up for Life

Mastercard

A first-quarter GDP retracement and the Atlanta Fed's latest GDP estimate for the second quarter signals we may already be in a recession.

4 No-Brainer Stocks to Buy if the U.S. Dips Into a Recession

Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.

Is a Beat Likely for Intuitive Surgical (ISRG) in Q2 Earnings?

This medical device stock is one to watch.

Will Intuitive Surgical Stock Continue to Dominate?

DexCom

Both of these disruptive healthcare companies could be big winners over the long term.

Better Bear Market Buy: DexCom vs. Intuitive Surgical

Not only do we believe the company will navigate well during the quarter, but we also find the stock to be undervalued, as discussed below.

Will Intuitive Surgical Stock See Higher Levels Post Q2 Results?

Align Technology

Even after losing nearly 65% of its market value in the first half of the year, Align Technology Inc. ( ALGN , Financial) still does not look like anything approaching a buy. The Phoenix-area company earned the dubious distinction of leading the steep decline among medical device providers in the first six months of 2022, according to health care consulting firm Evaluate.

Investors Wise to Steer Clear of Medtechs Providing Self-Pay Products, Services

Intuitive Surgical, Inc. (ISRG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intuitive Surgical, Inc. (ISRG) Expected to Beat Earnings Estimates: Should You Buy?

Attractive returns should be on the way for these companies' shareholders.

2 Top Healthcare Stocks to Buy and Hold for the Long Haul

Intuit

Fast-growing companies typically trade at a premium valuation as investors tend to be willing to pay up for that growth.

2 Undervalued Names Growing at High Rates

Lam Research

Zebra Technologies

Some of the top tech stocks you'll want to have in your portfolio for the next decade are on sale.

3 Smartest Tech Stocks to Buy in 2022 and Beyond

Amphenol

Costco

Dover

EPAM Systems

Alphabet

NextEra Energy

Paycom Software

QUALCOMM

Sherwin-Williams

The first half of 2022 was not the worst ever for equities, but it was bad enough.

10 Best Stocks to Boost Your Portfolio in the Second Half

Surgical demand for the robotic da Vinci system is recovering quickly as hospitals are getting out of the COVID-19 jam. Recent market volatility brought Intuitive Surgical below its intrinsic value.

Intuitive Surgical: Too Cheap For Robotic Surgery Leader

Airbnb

Broadcom

The predominantly growth-focused Nasdaq 100 is housing three incredible bargains.

3 Nasdaq 100 Stocks to Buy Hand Over Fist in July

Intuitive Surgical, Inc. (ISRG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Intuitive Surgical, Inc. (ISRG) Keep the Earnings Surprise Streak Alive?

AbbVie

American Tower

AutoZone

Palo Alto Networks

Long-term investors can emerge stronger from inevitable economic slowdowns with savvy picks.

These 5 Top Stocks Are Set to Outperform in a Recession

The FDA clears the integration of mobile cone-beam CT imaging technology with Intuitive's (ISRG) Ion Endoluminal System, enhancing a physician's ability to provide minimally invasive lung biopsy.

Intuitive (ISRG) New Lung Biopsy Imaging Technology Gets FDA Nod

Its stock is looking quite affordable compared to last year.

Intuitive Surgical Stock Is Primed for a Rebound. Here's Why

Intuitive's Ion System and Siemens Healthineers Cios Spin FDA clearance offers seamless cone beam CT scans during robotic bronchoscopy procedures Intuitive's Ion System and Siemens Healthineers Cios Spin FDA clearance offers seamless cone beam CT scans during robotic bronchoscopy procedures

Intuitive and Siemens Healthineers enhance scanning integration for Ion Endoluminal procedures

Boot Barn Hlds

CrowdStrike

Fiverr

Globant

Snap

Teladoc

These growth stocks offer healthy upside potential over the long-haul once the dust settles on the current macro-economic crisis. The post 7 Growth Stocks to Buy for a Bear Market appeared first on InvestorPlace.

7 Growth Stocks to Buy for a Bear Market

Disney

Innovative Industrial Properties

Jazz Pharmaceuticals

Opportunistic investors can snag some amazing deals with the Nasdaq and S&P 500 in a bear market.

Stock Market Plunge: 5 Unstoppable Stocks Begging to Be Bought

HubSpot

Cloudflare

SolarEdge Technologies

Block

Upstart Holdings

Growth stocks generally have a high level of earnings and are expected to grow at a fast pace. And these seven look like good investments.

News for Intuitive Surgical Stock (ISRG)